Potential of artificial intelligence to accelerate diagnosis and drug discovery for COVID-19

PeerJ

article

Indira Mikkili¹  Abraham Peele Karlapudi¹  T. C. Venkateswarulu¹  Vidya Prabhakar Kodali²  Deepika Sri Singh Macamdas¹  Krupanidhi Sreerama¹ 

[1] Biotechnology, Vignan’s Foundation for Science, Technology & Research;Biotechnology, Vikrama Simhapuri University

关键词: Machine learning;    Neural networks;    Drug discovery;    Reverse transcriptase polymerase chain reaction;    Artificial intelligence;    Computed tomography;    SARS CoV-2;    Pharmacogenomics;    Homology modeling;    Protein prediction;   

DOI  :  10.7717/peerj.12073

学科分类：社会科学、人文和艺术（综合）

来源: Inra

【 摘 要 】

The coronavirus disease (COVID-19) pandemic has caused havoc worldwide. The tests currently used to diagnose COVID-19 are based on real time reverse transcription polymerase chain reaction (RT-PCR), computed tomography medical imaging techniques and immunoassays. It takes 2 days to obtain results from the RT-PCR test and also shortage of test kits creating a requirement for alternate and rapid methods to accurately diagnose COVID-19. Application of artificial intelligence technologies such as the Internet of Things, machine learning tools and big data analysis to COVID-19 diagnosis could yield rapid and accurate results. The neural networks and machine learning tools can also be used to develop potential drug molecules. Pharmaceutical companies face challenges linked to the costs of drug molecules, research and development efforts, reduced efficiency of drugs, safety concerns and the conduct of clinical trials. In this review, relevant features of artificial intelligence and their potential applications in COVID-19 diagnosis and drug development are highlighted.

【 授权许可】

CC BY